LAGA

Laga Biologics is a biotechnology company focused on developing targeted therapies for bone and joint diseases, with a primary emphasis on treating chronic bone infections. The company's core technology involves a proprietary bone-targeting platform that utilizes bisphosphonate-like molecules to deliver high concentrations of antibiotics, such as vancomycin, directly to the site of bone infection (osteomyelitis). By concentrating the therapeutic agent at the bone surface, Laga Biologics aims to improve efficacy against biofilm-associated bacteria while minimizing systemic toxicity. Their lead programs are designed to address the significant clinical challenge of orthopedic implant-associated infections and chronic bone repair.